肝臓
Online ISSN : 1881-3593
Print ISSN : 0451-4203
ISSN-L : 0451-4203
速報
LDL cholesterolとHCV core regionはC型慢性肝炎に対するPeginterferon/Ribavirin併用療法の重要な治療前効果予測因子である
芥田 憲夫鈴木 文孝川村 祐介八辻 寛美瀬崎 ひとみ鈴木 義之保坂 哲也小林 正宏小林 万利子荒瀬 康司池田 健次熊田 博光
著者情報
ジャーナル フリー

2006 年 47 巻 9 号 p. 450-451

詳細
抄録
We evaluated 130 consecutive Japanese adults of HCV genotype 1b who received treatment with peginterferon (PEG-IFN) plus ribavirin (RBV) for 48 weeks, to investigate the pretreatment predictive factors of early virologic response (EVR) and sustained virological response (SVR). 75% of patients could achieve EVR, and 45% were SVR. Multivariate analysis identified low density lipoprotein cholesterol (LDL-C) (≥86mg/dl) and amino acid (aa) substitutions in HCV core region (Double wild type; arginine at aa 70 and leucine at aa 91) as independent and significant determinants of EVR. Furthermore, multivariate analysis identified LDL-C (≥86mg/dl), aa substitutions in core region (Double wild type), gender (male), ICG R15 (<10%), AST (<60IU/l) as determinants of SVR. In conclusion, LDL-C and aa substitutions in core region are important pretreatment predictors of response to treatment with PEG-IFN plus RBV in Japanese patients infected with genotype 1b.
著者関連情報
© 2006 一般社団法人 日本肝臓学会
前の記事
feedback
Top